Invivyd, Inc. (Nasdaq: IVVD) Earnings Report Highlights

Financial Performance - Invivyd, Inc. reported Q4 2025 revenue of $17.2 million, surpassing estimates of $15.5 million, indicating strong demand for PEMGARDA [2][5] - The revenue of $17.2 million represents a 25% increase year-over-year and a 31% increase quarter-over-quarter [2] - The company reported an earnings per share (EPS) of -$0.064, slightly below the estimated EPS of -$0.06 [1] Cash Position - By the end of 2025, Invivyd had cash and cash equivalents totaling $226.7 million, supported by over $200 million raised through financing transactions in the latter half of the year [2][5] - The company maintains a strong equity position with a debt-to-equity ratio of 0.010 and a robust current ratio of 7.24 [4] Clinical Development - Invivyd is advancing its DECLARATION Phase 3 pivotal clinical trial for VYD2311, a vaccine-alternative antibody aimed at preventing COVID-19 [3][5] - The trial has received Fast Track designation from the FDA, with top-line data expected by mid-2026 [3] - The trial has reached full enrollment, and the Independent Data Monitoring Committee (IDMC) has recommended the inclusion of pregnant and breastfeeding women [3] Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately -5.61, indicating negative earnings [4] - Its price-to-sales ratio is about 4.25, suggesting investors are willing to pay $4.25 for every dollar of sales [4] - The enterprise value to sales ratio is low at 0.052, which may imply undervaluation relative to its sales [4]